Advertisement

Coronary Venous Bypass Lesions

  • Judit Karacsonyi
  • Anil Poulose
  • Ivan Chavez
  • Yale Wang
  • Imre Ungi
  • Subhash Banerjee
  • Emmanouil S. Brilakis
Chapter

Abstract

Saphenous vein graft (SVG) percutaneous coronary interventions (PCIs) are common, currently representing approximately 6% of the overall PCI volume. SVG PCI is associated with higher risk of periprocedural complications and lower long-term patency compared with native coronary artery PCI; hence, the latter is preferred to SVG PCI whenever possible. Embolic protection devices and intragraft vasodilator administration can help to reduce the risk or consequences of distal embolization; however, they are currently underutilized. Drug-eluting stents can reduce the risk of in-stent restenosis and the need for repeat revascularization as compared with bare-metal stents in SVG lesions.

Keywords

Saphenous vein graft Percutaneous coronary intervention 

Notes

Disclosures

Dr. Banerjee: Research grants from Gilead and the Medicines Company; consultant/speaker honoraria from Covidien and Medtronic; ownership in MDCARE Global (spouse); intellectual property in HygeiaTel.

Dr. Brilakis: Consulting/speaker honoraria from Abbott Vascular, Asahi, Cardinal Health, Elsevier, GE Healthcare and St Jude Medical; research support from Boston Scientific and InfraRedx; spouse is employee of Medtronic.

The remaining authors have no conflicts of interest to disclose.

References

  1. 1.
    Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005;294(19):2446–54.CrossRefPubMedGoogle Scholar
  2. 2.
    Shroyer AL, Grover FL, Hattler B, Collins JF, McDonald GO, Kozora E, Lucke JC, Baltz JH, Novitzky D, The Veterans Affairs Randomized On/Off Bypass Study Group. On-pump versus off-pump coronary-artery bypass surgery. N Engl J Med. 2009;361(19):1827–37.CrossRefPubMedGoogle Scholar
  3. 3.
    Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, Thottapurathu L, Krasnicka B, Ellis N, Anderson RJ, Henderson W. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery results from a Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol. 2004;44(11):2149–56.CrossRefPubMedGoogle Scholar
  4. 4.
    Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol. 1996;28(3):616–26.CrossRefPubMedGoogle Scholar
  5. 5.
    Yahagi K, Kolodgie FD, Otsuka F, Finn AV, Davis HR, Joner M, Virmani R. Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis. Nat Rev Cardiol. 2016;13(2):79–98.CrossRefPubMedGoogle Scholar
  6. 6.
    Morrison DA, Sethi G, Sacks J, Henderson WG, Grover F, Sedlis S, Esposito R, Investigators of the Department of Veterans Affairs Cooperative Study AWESOME. Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomized trial and registry experience with post-CABG patients. J Am Coll Cardiol. 2002;40(11):1951–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Brilakis ES, Lee M, Mehilli J, Marmagkiolis K, Rodes-Cabau J, Sachdeva R, Kotsia A, Christopoulos G, Rangan BV, Mohammed A, Banerjee S. Saphenous vein graft interventions. Curr Treat Options Cardiovasc Med. 2014;16(5):301.CrossRefPubMedGoogle Scholar
  8. 8.
    Brilakis ES, Wang TY, Rao SV, Banerjee S, Goldman S, Shunk K, Kar B, Holmes DR Jr, Dai D, Chin CT, Harding TM, Roe MT. Frequency and predictors of drug-eluting stent use in saphenous vein bypass graft percutaneous coronary interventions: a report from the American College of Cardiology National Cardiovascular Data CathPCI registry. JACC Cardiovasc Interv. 2010;3(10):1068–73.CrossRefPubMedGoogle Scholar
  9. 9.
    Banerjee S, Brilakis ES. Embolic protection during saphenous vein graft interventions. J Invasive Cardiol. 2009;21(8):415–7.PubMedGoogle Scholar
  10. 10.
    Keeley EC, Velez CA, O'Neill WW, Safian RD. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. J Am Coll Cardiol. 2001;38(3):659–65.CrossRefPubMedGoogle Scholar
  11. 11.
    Brennan JM, Sketch MH Jr, Dai D, Trilesskaya M, Al-Hejily W, Rao SV, Brilakis E, Messenger JC, Shaw RE, Anstrom KJ, Peterson ED, Douglas PS. Safety and clinical effectiveness of drug-eluting stents for saphenous vein graft intervention in older individuals: results from the medicare-linked National Cardiovascular Data Registry((R)) CathPCI registry((R)) (2005-2009). Catheter Cardiovasc Interv. 2016;87(1):43–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Varghese I, Boatman DM, Peters CT, Daye J, Haider A, Roesle M, Banerjee S, Brilakis ES. Impact on contrast, fluoroscopy, and catheter utilization from knowing the coronary artery bypass graft anatomy before diagnostic coronary angiography. Am J Cardiol. 2008;101(12):1729–32.CrossRefPubMedGoogle Scholar
  13. 13.
    Eisenhauer MD, Malik JA, Coyle LC, Arendt MA. Impact of aorto-coronary graft markers on subsequent graft patency: a retrospective review. Catheter Cardiovasc Diagn. 1997;42(3):259–61.CrossRefGoogle Scholar
  14. 14.
    Dimas B, Lindsey JB, Banerjee S, Brilakis ES. ST-segment elevation acute myocardial infarction due to severe hypotension and proximal left subclavian artery stenosis in a prior coronary artery bypass graft patient. Cardiovasc Revasc Med. 2009;10(3):191–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Rigattieri S, Sciahbasi A, Brilakis ES, Burzotta F, Rathore S, Pugliese FR, Fedele S, Ziakas AG, Zhou YJ, Guzman LA, Anderson RA. Meta-analysis of radial versus femoral artery approach for coronary procedures in patients with previous coronary artery bypass grafting. Am J Cardiol. 2016;117(8):1248–55.CrossRefPubMedGoogle Scholar
  16. 16.
    Michael TT, Alomar M, Papayannis A, Mogabgab O, Patel VG, Rangan BV, Luna M, Hastings JL, Grodin J, Abdullah S, Banerjee S, Brilakis ES. A randomized comparison of the transradial and transfemoral approaches for coronary artery bypass graft angiography and intervention: the RADIAL-CABG trial (RADIAL versus femoral access for coronary artery bypass graft angiography and intervention). JACC Cardiovasc Interv. 2013;6(11):1138–44.CrossRefPubMedGoogle Scholar
  17. 17.
    Cooper L, Banerjee S, Brilakis ES. Crossover from radial to femoral access during a challenging percutaneous coronary intervention can make the difference between success and failure. Cardiovasc Revasc Med. 2010;11(4):266 e5–8.CrossRefGoogle Scholar
  18. 18.
    Wiper A, Mamas M, El-Omar M. Use of the GuideLiner catheter in facilitating coronary and graft intervention. Cardiovasc Revasc Med. 2011;12(1):68 e5–7.CrossRefGoogle Scholar
  19. 19.
    Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DE, Kaya U, Popma JJ, Ho KK, Kuntz RE. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation. 2002;105(11):1285–90.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Stone GW, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud A, Cambier P, Caputo RP, Turco M, Kovach R, Brodie B, Herrmann HC, Kuntz RE, Popma JJ, Ramee S, Cox DA. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation. 2003;108(5):548–53.CrossRefPubMedGoogle Scholar
  21. 21.
    Carrozza JP Jr, Mumma M, Breall JA, Fernandez A, Heyman E, Metzger C. Randomized evaluation of the TriActiv balloon-protection flush and extraction system for the treatment of saphenous vein graft disease. J Am Coll Cardiol. 2005;46(9):1677–83.CrossRefPubMedGoogle Scholar
  22. 22.
    Holmes DR, Coolong A, O'Shaughnessy C, Chauhan M, Van Langenhove G, Hall P, Vermeersch P, Verlee P, Popma JJ, Cutlip D, Kuntz RE. Comparison of the CardioShield filter with the guardwire balloon in the prevention of embolisation during vein graft intervention: results from the CAPTIVE randomised trial. EuroIntervention. 2006;2(2):161–8.PubMedGoogle Scholar
  23. 23.
    Mauri L, Cox D, Hermiller J, Massaro J, Wahr J, Tay SW, Jonas M, Popma JJ, Pavliska J, Wahr D, Rogers C. The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis embolic protection system: a randomized, prospective, multicenter clinical trial. J Am Coll Cardiol. 2007;50(15):1442–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Kereiakes DJ, Turco MA, Breall J, Farhat NZ, Feldman RL, McLaurin B, Popma JJ, Mauri L, Zimetbaum P, Massaro J, Cutlip DE. A novel filter-based distal embolic protection device for percutaneous intervention of saphenous vein graft lesions: results of the AMEthyst randomized controlled trial. JACC Cardiovasc Interv. 2008;1(3):248–57.CrossRefPubMedGoogle Scholar
  25. 25.
    Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44–122.CrossRefPubMedGoogle Scholar
  26. 26.
    Brennan JM, Al-Hejily W, Dai D, Shaw RE, Trilesskaya M, Rao SV, Brilakis ES, Anstrom KJ, Messenger JC, Peterson ED, Douglas PS, Sketch MH Jr. Three-year outcomes associated with embolic protection in saphenous vein graft intervention: results in 49 325 senior patients in the Medicare-linked National Cardiovascular Data Registry CathPCI Registry. Circ Cardiovasc Interv. 2015;8(3):e001403.CrossRefPubMedGoogle Scholar
  27. 27.
    Abdel-Karim AR, Papayannis AC, Mahmood A, Michael TT, Rangan BV, Makke L, Banerjee S, Brilakis ES. Role of embolic protection devices in ostial saphenous vein graft lesions. Catheter Cardiovasc Interv. 2012;80(7):1120–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Savage MP, Douglas JS Jr, Fischman DL, Pepine CJ, King SB 3rd, Werner JA, Bailey SR, Overlie PA, Fenton SH, Brinker JA, Leon MB, Goldberg S. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. N Engl J Med. 1997;337(11):740–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Hanekamp CE, Koolen JJ, Den Heijer P, Schalij MJ, Piek JJ, Bar FW, De Scheerder I, Bonnier HJ, Pijls NH. Randomized study to compare balloon angioplasty and elective stent implantation in venous bypass grafts: the Venestent study. Catheter Cardiovasc Interv. 2003;60(4):452–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Schachinger V, Hamm CW, Munzel T, Haude M, Baldus S, Grube E, Bonzel T, Konorza T, Koster R, Arnold R, Haase J, Probst P, vom Dahl J, Neumann FJ, Mudra H, Hennen B, Thiele L, Zeiher AM. A randomized trial of polytetrafluoroethylene-membrane-covered stents compared with conventional stents in aortocoronary saphenous vein grafts. J Am Coll Cardiol. 2003;42(8):1360–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Stankovic G, Colombo A, Presbitero P, van den Branden F, Inglese L, Cernigliaro C, Niccoli L, Bartorelli AL, Rubartelli P, Reifart N, Heyndrickx GR, Saunamaki K, Morice MC, Sgura FA, Di Mario C. Randomized evaluation of polytetrafluoroethylene-covered stent in saphenous vein grafts: the randomized evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts (RECOVERS) trial. Circulation. 2003;108(1):37–42.CrossRefPubMedGoogle Scholar
  32. 32.
    Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Bruining N, Van den Branden F, Van Langenhove G. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol. 2006;48(12):2423–31.CrossRefPubMedGoogle Scholar
  33. 33.
    Abizaid A, Weiner B, Bailey SR, Londero H. Use of a self-expanding super-elastic all-metal endoprosthesis; to treat degenerated SVG lesions: the SESAME first in man trial. Catheter Cardiovasc Interv. 2010;76(6):781–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, Van Langenhove G. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC trial. J Am Coll Cardiol. 2007;50(3):261–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Brilakis ES, Lichtenwalter C, Abdel-karim AR, de Lemos JA, Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S. Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial. JACC Cardiovasc Interv. 2011;4(2):176–82.CrossRefPubMedGoogle Scholar
  36. 36.
    Mehilli J, Pache J, Abdel-Wahab M, Schulz S, Byrne RA, Tiroch K, Hausleiter J, Seyfarth M, Ott I, Ibrahim T, Fusaro M, Laugwitz KL, Massberg S, Neumann FJ, Richardt G, Schomig A, Kastrati A. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet. 2011;378(9796):1071–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Stone GW, Goldberg S, O'Shaughnessy C, Midei M, Siegel RM, Cristea E, Dangas G, Lansky AJ, Mehran R. 5-year follow-up of polytetrafluoroethylene-covered stents compared with bare-metal stents in aortocoronary saphenous vein grafts the randomized BARRICADE (barrier approach to restenosis: restrict intima to curtail adverse events) trial. JACC Cardiovasc Interv. 2011;4(3):300–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Turco MA, Buchbinder M, Popma JJ, Weissman NJ, Mann T, Doucet S, Johnson WL Jr, Greenberg JD, Leadley K, Russell ME. Pivotal, randomized U.S. study of the Symbiottrade mark covered stent system in patients with saphenous vein graft disease: eight-month angiographic and clinical results from the Symbiot III trial. Catheter Cardiovasc Interv. 2006;68(3):379–88.CrossRefPubMedGoogle Scholar
  39. 39.
    Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, Saeed B, Gadiparthi C, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol. 2009;53(11):919–28.CrossRefPubMedGoogle Scholar
  40. 40.
    Hong YJ, Pichard AD, Mintz GS, Kim SW, Lee SY, Kim SY, Ahn Y, Jeong MH, Satler LF, Kent KM, Suddath WO, Weissman NJ, Kang JC, Waksman R. Outcome of undersized drug-eluting stents for percutaneous coronary intervention of saphenous vein graft lesions. Am J Cardiol. 2010;105(2):179–85.CrossRefPubMedGoogle Scholar
  41. 41.
    Gracida M, Romaguera R, Jacobi F, Gomez-Hospital JA, Cequier A. The MGuard coronary stent: safety, efficacy, and clinical utility. Vasc Health Risk Manag. 2015;11:533–9.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Grube E, Hauptmann KE, Muller R, Uriel N, Kaluski E. Coronary stenting with MGuard: extended follow-up of first human trial. Cardiovasc Revasc Med. 2011;12(3):138–46.CrossRefPubMedGoogle Scholar
  43. 43.
    Karatasakis A, Akhtar YN, Brilakis ES. Distal coronary perforation in patients with prior coronary artery bypass graft surgery: the importance of early treatment. Cardiovasc Revasc Med. 2016;17(6):412–7.CrossRefPubMedGoogle Scholar
  44. 44.
    Brilakis ES, O’Donnell CI, Penny W, Armstrong EJ, Tsai T, Maddox TM, Plomondon ME, Banerjee S, Rao SV, Garcia S, Nallamothu B, Shunk KA, Mavromatis K, Grunwald GK, Bhatt DL. Percutaneous coronary intervention in native coronary arteries versus bypass grafts in patients with prior coronary artery bypass graft surgery: insights from the veterans affairs clinical assessment, reporting, and tracking program. JACC Cardiovasc Interv. 2016;9(9):884–93.CrossRefPubMedGoogle Scholar
  45. 45.
    Brilakis ES, Rao SV, Banerjee S, Goldman S, Shunk KA, Holmes DR Jr, Honeycutt E, Roe MT. Percutaneous coronary intervention in native arteries versus bypass grafts in prior coronary artery bypass grafting patients a report from the national cardiovascular data registry. JACC Cardiovasc Interv. 2011;4(8):844–50.CrossRefPubMedGoogle Scholar
  46. 46.
    Michael TT, Karmpaliotis D, Brilakis ES, Fuh E, Patel VG, Mogabgab O, Alomar M, Kirkland BL, Lembo N, Kalynych A, Carlson H, Banerjee S, Lombardi W, Kandzari DE. Procedural outcomes of revascularization of chronic total occlusion of native coronary arteries (from a Multicenter United States Registry). Am J Cardiol. 2013;112(4):488–92.CrossRefPubMedGoogle Scholar
  47. 47.
    Brilakis ES, Banerjee S, Lombardi WL. Retrograde recanalization of native coronary artery chronic occlusions via acutely occluded vein grafts. Catheter Cardiovasc Interv. 2010;75(1):109–13.PubMedGoogle Scholar
  48. 48.
    Varghese I, Samuel J, Banerjee S, Brilakis ES. Comparison of percutaneous coronary intervention in native coronary arteries vs. bypass grafts in patients with prior coronary artery bypass graft surgery. Cardiovasc Revasc Med. 2009;10(2):103–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Sdringola S, Assali A, Ghani M, Yepes A, Rosales O, Schroth GW, Fujise K, Anderson HV, Smalling RW. Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow-no reflow phenomenon. Catheter Cardiovasc Interv. 2000;51(4):394–9.CrossRefPubMedGoogle Scholar
  50. 50.
    Zoghbi GJ, Goyal M, Hage F, Meyers RP, Papapietro SE, Brott BC, Misra VK, Iskandrian AE, Hillegass WB. Pretreatment with nitroprusside for microcirculatory protection in saphenous vein graft interventions. J Invasive Cardiol. 2009;21(2):34–9.PubMedGoogle Scholar
  51. 51.
    Fischell TA, Subraya RG, Ashraf K, Perry B, Haller S. «Pharmacologic» distal protection using prophylactic, intragraft nicardipine to prevent no-reflow and non-Q-wave myocardial infarction during elective saphenous vein graft intervention. J Invasive Cardiol. 2007;19(2):58–62.PubMedGoogle Scholar
  52. 52.
    Michaels AD, Appleby M, Otten MH, Dauterman K, Ports TA, Chou TM, Gibson CM. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial. J Invasive Cardiol. 2002;14(6):299–302.PubMedGoogle Scholar
  53. 53.
    Roffi M, Mukherjee D, Chew DP, Bhatt DL, Cho L, Robbins MA, Ziada KM, Brennan DM, Ellis SG, Topol EJ. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation. 2002;106(24):3063–7.CrossRefPubMedGoogle Scholar
  54. 54.
    Coolong A, Baim DS, Kuntz RE, O'Malley AJ, Marulkar S, Cutlip DE, Popma JJ, Mauri L. Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients. Circulation. 2008;117(6):790–7.CrossRefPubMedGoogle Scholar
  55. 55.
    Sachdeva A, Bavisetty S, Beckham G, Shen AY, Aharonian V, Mansukhani P, Stone GW, Leon M, Moses J, Moore N, Hyett R, Contreras R, Brar SS. Discontinuation of long-term clopidogrel therapy is associated with death and myocardial infarction after saphenous vein graft percutaneous coronary intervention. J Am Coll Cardiol. 2012;60(23):2357–63.CrossRefPubMedGoogle Scholar
  56. 56.
    Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L, Investigators DS. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315(16):1735–49.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Abdel-Karim AR, Banerjee S, Brilakis ES. Percutaneous intervention of acutely occluded saphenous vein grafts: contemporary techniques and outcomes. J Invasive Cardiol. 2010;22(6):253–7.PubMedGoogle Scholar
  58. 58.
    Ebersole D, Dahm JB, Das T, Madyoon H, Vora K, Baker J, Hilton D, Alderman E, Topaz O. Excimer laser revascularization of saphenous vein grafts in acute myocardial infarction. J Invasive Cardiol. 2004;16(4):177–80.PubMedGoogle Scholar
  59. 59.
    Fiorina C, Meliga E, Chizzola G, Curello S, Tayeh O, Vizzardi E, Dei Cas L, Ettori F. Early experience with a new approach for percutaneous intervention of totally occluded saphenous vein graft: is the flow the best thrombolytic? EuroIntervention. 2010;6(4):461–6.CrossRefPubMedGoogle Scholar
  60. 60.
    Teramoto T, Tsuchikane E, Matsuo H, Suzuki Y, Ito T, Ito T, Habara M, Nasu K, Kimura M, Kinoshita Y, Terashima M, Asakura Y, Matsubara T, Suzuki T. Initial success rate of percutaneous coronary intervention for chronic total occlusion in a native coronary artery is decreased in patients who underwent previous coronary artery bypass graft surgery. JACC Cardiovasc Interv. 2014;7(1):39–46.CrossRefPubMedGoogle Scholar
  61. 61.
    Al-Lamee R, Ielasi A, Latib A, Godino C, Ferraro M, Arioli F, Mussardo M, Piraino D, Figini F, Carlino M, Montorfano M, Chieffo A, Colombo A. Clinical and angiographic outcomes after percutaneous recanalization of chronic total saphenous vein graft occlusion using modern techniques. Am J Cardiol. 2010;106(12):1721–7.CrossRefPubMedGoogle Scholar
  62. 62.
    Jim MH, Ho HH, Ko RL, Siu CW, Yiu KH, Lau CP, Chow WH. Paclitaxel-eluting stents for chronically occluded saphenous vein grafts (EOS) study. J Interv Cardiol. 2010;23(1):40–5.CrossRefPubMedGoogle Scholar
  63. 63.
    Nguyen-Trong PK, Alaswad K, Karmpaliotis D, Lombardi W, Grantham JA, Lembo N, Kandzari D, Karatasakis A, Karacsonyi J, Danek BA, Rangan BV, Roesle M, Ayers CR, Thompson CA, Banerjee S, Brilakis ES. Use of saphenous vein bypass grafts for retrograde recanalization of coronary chronic total occlusions: insights from a multicenter registry. J Invasive Cardiol. 2016;28(6):218–24.PubMedGoogle Scholar
  64. 64.
    Mhatre A, Uretsky BF, Sachdeva R. Substrate for complications. J Invasive Cardiol. 2012;24(7):E153–6.PubMedGoogle Scholar
  65. 65.
    Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Holper EM, Haagen D, Saeed B, Iturbe JM, Shunk K, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S, Brilakis ES. Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial. JACC Cardiovasc Interv. 2009;2(9):855–60.CrossRefPubMedGoogle Scholar
  66. 66.
    Ashby DT, Dangas G, Aymong EA, Iakovou I, Kuepper F, Mehran R, Stone GW, Leon MB, Moses JW. Effect of percutaneous coronary interventions for in-stent restenosis in degenerated saphenous vein grafts without distal embolic protection. J Am Coll Cardiol. 2003;41(5):749–52.CrossRefPubMedGoogle Scholar
  67. 67.
    Hong YJ, Jeong MH, Ahn Y, Kang JC, Mintz GS, Kim SW, Lee SY, Kim SY, Pichard AD, Satler LF, Waksman R, Weissman NJ. Impact of lesion location on intravascular ultrasound findings and short-term and five-year long-term clinical outcome after percutaneous coronary intervention for saphenous vein graft lesions. Int J Cardiol. 2013;167(1):29–33.CrossRefPubMedGoogle Scholar
  68. 68.
    Wood FO, Badhey N, Garcia B, Abdel-karim AR, Maini B, Banerjee S, Brilakis ES. Analysis of saphenous vein graft lesion composition using near-infrared spectroscopy and intravascular ultrasonography with virtual histology. Atherosclerosis. 2010;212(2):528–33.CrossRefPubMedGoogle Scholar
  69. 69.
    Brilakis ES, Maniu C, Wahl M, Barsness G. Unstable angina due to stent fracture. J Invasive Cardiol. 2004;16(9):545.PubMedGoogle Scholar
  70. 70.
    Abdel-Karim AR, Da Silva M, Lichtenwalter C, de Lemos JA, Obel O, Addo T, Roesle M, Haagen D, Rangan BV, Makke L, Jeroudi OM, Raghunathan D, Saeed B, Bissett JK, Sachdeva R, Voudris VV, Karyofillis P, Kar B, Rossen J, Fasseas P, Berger P, Banerjee S, Brilakis ES. Prevalence and outcomes of intermediate saphenous vein graft lesions: findings from the stenting of saphenous vein grafts randomized-controlled trial. Int J Cardiol. 2013;168(3):2468–73.CrossRefPubMedGoogle Scholar
  71. 71.
    Aqel R, Zoghbi GJ, Hage F, Dell'Italia L, Iskandrian AE. Hemodynamic evaluation of coronary artery bypass graft lesions using fractional flow reserve. Catheter Cardiovasc Interv. 2008;72(4):479–85.CrossRefPubMedGoogle Scholar
  72. 72.
    Rodes-Cabau J, Bertrand OF, Larose E, Dery J-P, Rinfret S, Bagur R, Proulx G, Nguyen CM, Cote M, Landcop M-C, Boudreault J-R, Rouleau J, Roy L, Gleeton O, Barbeau G, Noel B, Courtis J, Dagenais GR, Despres J-P, DeLarochelliere R. Comparison of plaque sealing with paclitaxel-eluting stents versus medical therapy for the treatment of moderate nonsignificant saphenous vein graft lesions. The moderate VEin graft LEsion stenting with the Taxus stent and intravascular ultrasound (VELETI) pilot trial. Circulation. 2009;120:1978–86.CrossRefPubMedGoogle Scholar
  73. 73.
    Rodes-Cabau J, Bertrand OF, Larose E, Dery JP, Rinfret S, Urena M, Jerez M, Nombela-Franco L, Ribeiro HB, Allende R, Proulx G, Nguyen CM, Boudreault JR, Rouleau J, Roy L, Gleeton O, Barbeau G, Noel B, Cote M, Despres JP, Dagenais GR, DeLarochelliere R. Five-year follow-up of the plaque sealing with paclitaxel-eluting stents vs medical therapy for the treatment of intermediate nonobstructive saphenous vein graft lesions (VELETI) trial. Can J Cardiol. 2014;30(1):138–45.CrossRefPubMedGoogle Scholar
  74. 74.
    Rodes-Cabau J, Jolly SS, Cairns J, Mansour S, L’Allier PL, Teefy PJ, Graham JJ, Le May MR, Cantor WJ, Wood D, Balasubramanian K, DeLarochelliere R, Dzavik V, VELETI II Investigators. Sealing intermediate nonobstructive coronary saphenous vein graft lesions with drug-eluting stents as a new approach to reducing cardiac events: a randomized controlled trial. Circ Cardiovasc Interv. 2016;9(11):e004336.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Judit Karacsonyi
    • 1
    • 2
  • Anil Poulose
    • 3
  • Ivan Chavez
    • 3
  • Yale Wang
    • 3
  • Imre Ungi
    • 2
  • Subhash Banerjee
    • 1
  • Emmanouil S. Brilakis
    • 1
    • 3
  1. 1.VA North Texas Health Care System and UT Southwestern Medical CenterDallasUSA
  2. 2.Division of Invasive Cardiology, Second Department of Internal Medicine and Cardiology CenterUniversity of SzegedSzegedHungary
  3. 3.Minneapolis Heart InstituteMinneapolisUSA

Personalised recommendations